Literature DB >> 15468599

Multicellular tumor spheroids in gene therapy and oncolytic virus therapy.

Martine L M Lamfers1, Akseli Hemminki.   

Abstract

Multicellular clusters of cells, or spheroids, can be grown and sustained in vitro, facilitating various cancer research and treatment approaches. As spheroids are three-dimensional and retain many of the cell types and features present in the original clinical tissues, they provide an important link between two-dimensional cell lines and in vivo xenograft studies. With regards to gene therapy and replication-competent oncolytic viruses in particular, spheroids allow sustained viability of primary tumor cells in vitro, a requirement for reliable analysis of replication. Analysis of clinical samples is of paramount importance for preclinical evaluation of candidate anticancer agents.

Entities:  

Mesh:

Year:  2004        PMID: 15468599

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  4 in total

1.  A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.

Authors:  T Ranki; A Kanerva; A Ristimäki; T Hakkarainen; M Särkioja; L Kangasniemi; M Raki; P Laakkonen; S Goodison; A Hemminki
Journal:  Gene Ther       Date:  2006-08-10       Impact factor: 5.250

2.  A three-dimensional assay for measurement of viral-induced oncolysis.

Authors:  J T Lam; A Hemminki; A Kanerva; K B Lee; J L Blackwell; R Desmond; G P Siegal; D T Curiel
Journal:  Cancer Gene Ther       Date:  2007-01-19       Impact factor: 5.987

Review 3.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

4.  Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition.

Authors:  Stuart J Smith; Martin Wilson; Jennifer H Ward; Cheryl V Rahman; Andrew C Peet; Donald C Macarthur; Felicity R A J Rose; Richard G Grundy; Ruman Rahman
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.